Angiotech appoints Jeffrey P. Walker as Senior Vice President, Research and Development
06 Juli 2006 - 3:30PM
PR Newswire (US)
VANCOUVER, July 6 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced the appointment of Jeffrey P. Walker, MD as Senior Vice
President, Research and Development. Reporting to Dr. William
Hunter, Angiotech's President and Chief Executive Officer, Dr.
Walker will lead the research and development team on a global
basis and build upon a strong product pipeline to further support
Angiotech's business strategy to capture value through the
commercialization of internally developed products. "Dr. Walker
brings to Angiotech a rare combination of experience including work
as a practising emergency physician, a wealth of R&D knowledge
from working at other pharmaceutical companies, and practical
experience working at medical device companies with drug-device
combination products, such as drug-eluting stents," said Dr.
William Hunter. "We welcome Jeff to our management team, and
believe that our ability to attract this level of talent to
Angiotech is yet another indicator of our successful evolution to a
fully-commercialized company within the past year," added Dr.
Hunter. Dr. Walker has over 14 years' experience at pharmaceutical
and medical device companies in developing combination medical
devices, drug development, and drug delivery technologies. Prior to
joining Angiotech, Dr. Walker was Vice President, Advanced
Technology/New Ventures at Medtronic Vascular, Inc. During his
career at Medtronic, Dr. Walker also held the position of Vice
President, Science & Technology and was responsible for the
development of next-generation medical devices that integrated
biotechnology and pharmaceuticals. He also held senior positions in
research and development at Miravant Pharmaceuticals based in Santa
Barbara, California. In 1994, he formed his own start-up medical
device company focused on solid tumor drug delivery and treatment.
A graduate of the UCLA School of Medicine, Dr. Walker was an
Emergency Physician at the St. Agnes Medical Center in Fresno,
California for seven years. He also holds a B.A. in Psychobiology
with post-graduate work in Anatomy and Physiology. About Angiotech
Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a global
specialty pharmaceutical and medical device company with 14
facilities in 6 countries and over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Note on Forward Looking Statement:
Statements contained in this press release or in our other written
or oral public communications that are not based on historical or
current fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Such forward-looking statements are based
on assumptions that involve known and unknown risks, uncertainties
and other factors that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Angiotech(R) is a trademark of Angiotech
Pharmaceuticals, Inc. and its subsidiaries. All rights reserved.
CONTACT: Analysts and Institutional Investors: Janet Craig, VP,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., ; Media and Retail Investors: Jodi Regts,
Manager, Corporate Communications, Angiotech Pharmaceuticals, Inc.,
, (604) 221-7930 DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Institutional Investors: Janet Craig, VP,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., ; Media and Retail Investors: Jodi Regts,
Manager, Corporate Communications, Angiotech Pharmaceuticals, Inc.,
, (604) 221-7930
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024